Avastin (bevacizumab) - 400mg - For Intravenous Use

Object Details

Genentech, Inc.

Description (Brief): (From box) For Intravenous Use; (From insert); Metastatic Colorectal Cancer (mCRC) Avastin is indicated for the first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-flurouracil-based chemotherapy.; Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Avastin is indicated for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel.; Glioblastoma Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate. There are no data demonstrating an improvement in disease-related symptoms or increased survival with Avastin.; Metastatic Renal Cell Carcinoma (mRCC) Avastin is indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa.
Location: Currently not on view

Physical Description: metal (overall material); plastic (overall material); glass (overall material); cardboard (overall material); bevacizumab, 400 mg (20mg/mL) (overall ingredient)
Measurements: overall: 1 1/2 in x 2 3/4 in x 5 1/4 in; 3.81 cm x 6.985 cm x 13.335 cm; avastin bottle: 2 1/2 in x 1 1/4 in; 6.35 cm x 3.175 cm; overall: 5 1/4 in x 2 3/4 in x 1 1/2 in; 13.335 cm x 6.985 cm x 3.81 cm

See more items in: Medicine and Science: Medicine; Health & Medicine; The Antibody Initiative; Antibody Initiative: Monoclonal Antibodies

National Museum of American History

GUID (Link to Original Record): https://n2t.net/ark:/65665/ng49ca746ad-d911-704b-e053-15f76fa0b4fa